3rdannual ADC Summit – 19/20 May 2014Holiday Inn Regents Park Hotel, London UK SMi’s 3rd annual Antibody Drug Conjugates Summit comes at the perfect time to focus on innovative manufacturing techniques, preclinical and clinical data and next generation ADCs, bringing together key industry experts from academia, pharma and biotech companies. Join us and hear case studies, presentations and round tables demonstrating how to maximise the therapeutic index of your ADC and how this form of empowered antibody is transforming next-generation antibody therapeutics. KEY REASONS TO ATTED:Hear cutting edge presentations and key case studies from leading ADCs experts on key topics such as nano-delivery systems, advancing preclinical development to accelerate ADCs into the clinic, next generation ADCs and manufacturing challengesNetwork and learn from industry and academic opinion leaders including Photobiotics, Medlmmune, Spirogen, Synthon plus many more…Learn about latest developments pertaining to the components of ADCs (payload, antibody and linker)Join the debate in our round table session to discuss creative strategies in making the “smart bomb” more intelligent when building your oncology arsenal KEY SPEAKERS WILL INCLUDE:Dr Mahendra Deonarain, Chief Scientific Officer, PhotobioticsDr Adeela Kamal, Associate Director, R&D, Oncology Research, MedImmunePhilip Howard, PhD, Chief Scientific Officer, Spirogen LimitedDr Trevor Hallam, Chief Scientific Officer, Sutro BiopharmaDr Ronald Elgersma, Project Leader, Antibody-Drug Conjugates, SynthonDr Erica Hong, Scientist, ImmunoGenDr Hagop Youssoufian, Executive Vice President of R&D, ProgenicsDr Pamela Trail, Vice President Oncology, Regeneron